Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1998-5-28
pubmed:abstractText
The definition of the FP-receptor is currently based on the functional potency of agonists. Functional studies suggest that the FP-receptor has particular sensitivity to PGF2 alpha and certain PGF2 alpha analogs but is also stimulated by PGD2 and PGE2. In order to examine the concept that these responses involve a single (FP) receptor, we compared functional responses with radioligand binding competition studies. In Swiss 3T3 cells, an identical potency rank order was obtained for Ca2+ transient signals and competition at binding sites for 3H-PGF2 alpha and 3H-17-phenyl PGF2 alpha (i.e., 17-phenyl PGF2 alpha > PGF2 alpha > PGD2 > PGE2), suggesting interaction at a single receptor. This conclusion was further supported by successive addition studies where cells pretreated with a maximally effective dose of PGF2 alpha were refractory to subsequent addition of PGF2 alpha, PGD2, or PGE2 but not PDGF. We also performed competition binding studies in the rat colon and uterus as representative tissues where the functional potency rank order is inconsistent with an FP receptor or any other prostanoid receptor subtype. Radioligand binding studies involving 3H-17-phenyl PGF2 alpha and 3H-PGE2 in the rat colon and uterus indicated the co-existence of both FP and EP3 receptors according to the competition afforded by natural PGs and selective analogs for FP and EP3 receptors. Thus, the FP-receptor can be identified in a mixed population of prostanoid receptors and this lends further support to the FP-receptor as a discrete entity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0065-2598
pubmed:author
pubmed:issnType
Print
pubmed:volume
400A
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
223-7
pubmed:dateRevised
2003-11-14
pubmed:meshHeading
pubmed:year
1997
pubmed:articleTitle
Identification of the FP-receptor as a discrete entity by radioligand binding in biosystems that exhibit different functional rank orders of potency in response to prostanoids.
pubmed:affiliation
Department of Biological Sciences, Allergan, Inc., Irvine, CA 92713-9534, USA.
pubmed:publicationType
Journal Article